Acadia Pharmaceuticals (ACAD) Cash from Operations (2010 - 2026)

Acadia Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 33981000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 67.2% year-over-year to 33981000.0; the TTM figure through Mar 2026 stood at 123494000.0 (down 17.1% YoY), while the FY2025 annual figure was 109836000.0, down 30.36% from the prior year.
• Cash from Operations for Q1 2026 stood at 33981000.0, up from 48731000.0 in the prior quarter.
• The five-year high for Cash from Operations was 85389000.0 in Q4 2023, with the low at 76329000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 20323000.0 (2025), against an average of 12011941.18.
• Peak annual rise in Cash from Operations reached 457.97% in 2023, while the deepest fall reached 8009.35% in 2023.
• Acadia Pharmaceuticals' Cash from Operations stood at 23854000.0 in 2022, then surged by 457.97% to 85389000.0 in 2023, then slumped by 52.71% to 40381000.0 in 2024, then plunged by 220.68% to 48731000.0 in 2025, then surged by 169.73% to 33981000.0 in 2026.
• Business Quant data shows ACAD's Cash from Operations at 33981000.0 in Q1 2026, 48731000.0 in Q4 2025, and 74288000.0 in Q3 2025.